| 20.55 -0.34 (-1.63%) | 05-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 26.67 | 1-year : | 29.44 |
| Resists | First : | 22.83 | Second : | 25.2 |
| Pivot price | 20.7 |
|||
| Supports | First : | 19 | Second : | 15.8 |
| MAs | MA(5) : | 20.94  |
MA(20) : | 21.25 |
| MA(100) : | 21.88 |
MA(250) : | 17.11 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 41 |
D(3) : | 42.2 |
| RSI | RSI(14): 42.8 |
|||
| 52-week | High : | 25.59 | Low : | 8.58 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SNDX ] has closed above bottom band by 43.7%. Bollinger Bands are 14.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 21.27 - 21.37 | 21.37 - 21.47 |
| Low: | 20.15 - 20.28 | 20.28 - 20.4 |
| Close: | 20.31 - 20.52 | 20.52 - 20.72 |
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Thu, 14 May 2026
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential - Insider Monkey
Thu, 14 May 2026
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential - Yahoo Finance
Thu, 14 May 2026
Does Expanded Revuforj Leukemia Data Set Change The Bull Case For Syndax Pharmaceuticals (SNDX)? - simplywall.st
Tue, 12 May 2026
Leukemia drug revumenib lands 12 studies at European Hematology meeting - Stock Titan
Wed, 06 May 2026
Eight new Syndax hires get stock options for 162,100 shares - Stock Titan
Wed, 06 May 2026
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 89 (M) |
| Shares Float | 75 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 115.6 (%) |
| Shares Short | 20,970 (K) |
| Shares Short P.Month | 20,490 (K) |
| EPS | -2.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.74 |
| Profit Margin | -112.1 % |
| Operating Margin | -52.8 % |
| Return on Assets (ttm) | -25.2 % |
| Return on Equity (ttm) | -189.6 % |
| Qtrly Rev. Growth | 223.6 % |
| Gross Profit (p.s.) | -0.57 |
| Sales Per Share | 2.45 |
| EBITDA (p.s.) | -2.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -278 (M) |
| Levered Free Cash Flow | -188 (M) |
| PE Ratio | -7.37 |
| PEG Ratio | 0 |
| Price to Book value | 27.77 |
| Price to Sales | 8.37 |
| Price to Cash Flow | -6.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|